sadad

1
Outsourcing the Discovery of Alzheimer's Disease
Diabetes drugs . Scottish Biomedicals
Experiences
2
Company Overview
3
Successful Partnerships
4
Scientific Expertise
5
Core Strengths
6
Range of Collaborations
7
Business Model
8
Drug Discovery Capabilities Expertise
9
Research Collaborations
10
Unique Discovery Products
11
Target Class Success Rate
12
Novel Fast-Track (PinpointTM) Programs
Oncology animal tumour studies
ongoing Alzheimers Disease (proprietary target
4 novel lead series identified) Asthma
(PDE3/4 inhibitor) PHT (PDE 4/5
inhibitor) Diabetes (11b-HSD) Anti-inflammatory
(PDE 4 inhibitor)
13
Summary
14
Therapeutic Expertise

Expertise in CNS
Expertise in Diabetes
15
Drug Discovery Capabilities
Human Brain (AD, SZ, Parkinsons)
Human muscle Human adipose tissue
Tissue Acquisition
Novel AD gene identified patented
Lead optimisation
Target identification
Medicinal Chemistry
Client patented CNS specific genes
HTS
EPAC Activators
Novel 11b-HSD1 inhibitors
Novel PTP-1B inhibitors
16
CNS - Our Success

• Ethical Human brain tissue acquisition
• Identification validation of novel CNS disease
  targets (genomics proteomics)
• Assay development and HTS
• Behavioural studies
• Fast-Track Opportunities (available for
  co-development/licensing)
• Novel target ID Patent - Scottish Biomedical
  has identified a novel target for Alzheimers
  disease and potent small molecule activators of
  this target
• Design of custom cyclic nucleotide signalling
  gene array
• Cloning, expression and Epac activity assay
  development
• PinpointTM screening of Scottish Biomedical Lead
  Generation Library
• Client Project
• Scottish Biomedical sourced brain tissue bloods
  for microarray SNP analysis
• We have discovered 7 CNS genes novel pathway
  which has been patented by client

17
Diabetes Assays

• We have developed HTS assays to meet clients
  specific requirements
• Example Diabetes Assays carried out
• 11-hydroxysteroid dehydrogenase (HSD-1 2,
  human mouse)
• Phosphatase profiling
• Whole cell PTP-1b assay
• PEPCK-CAT reporter assay
• GLUT 4 Mobilisation Assay
• 2-deoxy-D-14Cglucose (DOG) uptake assay

• Chemiluminescence
• Radioactive
• Luminescence
• Absorption
• Fluorescence polarisation

• Kinase assay
• Receptor binding assay
• Lead Generation Library screening

18
Diabetes - our success

• Scottish Biomedical has identified validated
  targets which have been screened using our
  proprietary PinpointTM technology.
• Resulted in identification of novel patentable
  compounds outside existing intellectual property.
  Our Diabetes Fast-Track Opportunities are
  available for co-development or licensing
• Examples of Success
• PTP-1B Through screening the Scottish
  Biomedical Lead Generation Library, followed by
  early chemical optimisation we have identified a
  potent, selective, PTP-1B inhibitor with
  potential therapeutic value in the treatment of
  diabetes obesity
• 11b-HSD1 We have identified an potent selective
  11b-HSD1 inhibitor from a Pinpoint screen of the
  Scottish Biomedical Lead Generation Library
• Target ID Diabetes target identification
  through gene array analysis of ethically acquired
  tissue

19
Mr Simon Bury Tel [phone] Email
simon.bury_at_scottish-biomedical.com Web
www.scottish-biomedical.com